We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
DuPont de Nemours Inc | NYSE:DD | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.08 | -0.10% | 77.67 | 78.38 | 77.14 | 78.38 | 2,391,433 | 01:00:00 |
By Austen Hufford
Dow Chemical Co. and DuPont Co. said their merger's end date was being pushed back but added it was still on track as DuPont moved forward with plans to divest assets, a condition of European Union approval for the deal.
The companies now expect the deal to close in August 2017, after being delayed by intense regulatory scrutiny. When the deal was first announced in Dec. 2015, it was expected to close in the first half of 2016.
Earlier this week, the European Union's competition watchdog cleared the merger on the condition they sell parts of DuPont's global pesticides business and associated research and development, as well as Dow's acid copolymers and ionomers business.
Divestitures are commonly required in large deals to assuage concerns over market power and consolidation within specific markets and industries.
Following the EU decision, DuPont said Friday that it would sell its pesticide assets to FMC Corporation for that company's health and nutrition business and cash. FMC will buy DuPont's chewing pest insecticide portfolio, its global cereal broadleaf herbicides and a substantial portion of its global crop protection research-and-development efforts. DuPont is getting FMC's health-and-nutrition business and will also receive $1.2 billion in cash.
In 2017, FMC expects the units it is buying to generate about $1.5 billion in revenue. The health-and-nutrition business had 2016 revenue of $743.5 million.
Dow and DuPont said they still expect their merger to generate about $3 billion of cost synergies and $1 billion of growth synergies.
"Today's announced transaction enables us to satisfy the European Commission's approval conditions, while maintaining the strategic logic and value creation potential of our merger," DuPont Chief Executive Edward Breen said.
Write to Austen Hufford at austen.hufford@wsj.com
(END) Dow Jones Newswires
March 31, 2017 07:01 ET (11:01 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year DuPont de Nemours Chart |
1 Month DuPont de Nemours Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions